Analysts bullish on this LargeCap Pharma stock after Q1 earnings; expect up to 20%
On Monday, July 28, Torrent Pharmaceuticals reported outstanding performance for the first quarter of fiscal 2025-26, with consolidated net profit up 20% year-on-year to Rs 548 crore. Growth is driven by steady sales in major markets including India, the United States, Brazil and Germany. After the earnings, how should investors deal with the stock of LargeCap Company now? Analysts of outstanding brokers – jpmorgan, Jefferies and Citi tested positive for the drug stock, raising their target to Rs 4,380, up 20% from Monday’s closing ceremony.
Here is what brokers recommend to Torrent Pharma stock after Q1 performance:
JPMorgan Chase has a rating of “overweight” and has raised its target price from Rs 3,800 to Rs 4,000.
Two brokers, Jefferies and Citi, have made a “buy” call to pharmaceutical stocks, raising their targets to Rs 4,200 and Rs 4,380 respectively.
Torrent Pharma Q1FY26 results
Here’s how LargeCap Pharma Company’s first quarter earnings:
- Torrent Pharma Net Profit: Rs 5.48 crore (20% year-on-year)
- Operating revenue: Rs 3,178 crore (11% year-on-year)
- India Revenue: Rs 181.11 crore (11% year-on-year)
- US revenue: Rs 308 crore (19% year-on-year)
- Brazil revenue: Rs 218 crore (11% year-on-year)
- German revenue: Rs 308 crore (up 9% year-on-year)
